ARS Pharmaceuticals, Inc. (SPRY) SEC filings

SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/30

$3.89+0.08 (+2.10%)

Close on Nov 13, 2026Market cap $386.85MP/E –Yield –

SEC filings

40 of ARS Pharmaceuticals's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Jul 15, 2026	Jul 17, 2026	SEC EDGAR
Current report	8-K	Jul 6, 2026	Jul 7, 2026	SEC EDGAR
Current report	8-K	Jun 24, 2026	Jun 25, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 15, 2026	SEC EDGAR
Current report	8-K	May 15, 2026	May 15, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 13, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 24, 2026	Apr 29, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 9, 2026	SEC EDGAR
Current report	8-K	Mar 9, 2026	Mar 9, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 10, 2025	SEC EDGAR
Current report	8-K	Nov 10, 2025	Nov 10, 2025	SEC EDGAR
Current report	8-K	Sep 29, 2025	Sep 29, 2025	SEC EDGAR
Current report	8-K	Aug 13, 2025	Aug 28, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Aug 13, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Jun 25, 2025	Jun 26, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	May 2, 2025	May 2, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 25, 2025	Apr 29, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 20, 2025	SEC EDGAR
Current report	8-K	Mar 20, 2025	Mar 20, 2025	SEC EDGAR
Current report	8-K	Mar 5, 2025	Mar 5, 2025	SEC EDGAR
Current report	8-K	Jan 13, 2025	Jan 13, 2025	SEC EDGAR
Quarterly report, amended	10-Q/A	Sep 30, 2024	Dec 6, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 13, 2024	SEC EDGAR
Current report	8-K	Nov 13, 2024	Nov 13, 2024	SEC EDGAR
Current report	8-K	Nov 9, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Oct 8, 2024	Oct 15, 2024	SEC EDGAR
Current report	8-K	Sep 17, 2024	Sep 23, 2024	SEC EDGAR
Current report	8-K	Aug 9, 2024	Aug 12, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 6, 2024	SEC EDGAR
Current report	8-K	Aug 6, 2024	Aug 6, 2024	SEC EDGAR
Current report	8-K	Jun 28, 2024	Jun 28, 2024	SEC EDGAR
Current report	8-K	Jun 27, 2024	Jun 28, 2024	SEC EDGAR
Current report	8-K	Jun 20, 2024	Jun 21, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in ARS Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SPRY.

Compare: SPRY vs ZVRA · SPRY vs ETON · SPRY vs AGIO · SPRY vs VSTM · SPRY vs KPTIQ

Revenue growth-14.5% · median 110.0%

Operating margin-161.5% · median -56.2%

Net margin-163.6% · median -153.3%

Company	Revenue	Growth
KPTIQ	$146.62M	+6.8%
ETON	$141.06M	+100.6%
AGIO	$140.84M	+214.4%
ZVRA	$136.07M	+119.4%
SPRY	$122.14M	-14.5%
VSTM	$100.30M	–

Company

Next earnings (est.): Mar 8, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 158
Held by institutions: 91.2%
Auditor: Ernst & Young LLP
SEC CIK: 1671858

Advertisement
300 × 250

See a number that looks wrong?